AGIOS PHARMACEUTICALS, INC. (AGIO) Operating Margin
- Operating margin · 12 months: Value -466.78%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -466.78% | Operating income / revenue. Period ending 2026-06-30. $-459.02M ÷ $98.34M × 100 ≈ -466.78% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -459.02M USD | Operating Income (Loss) |
| Revenue | 98.34M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 7.87M USD | Cost of Goods and Services Sold |
| Research and development | 356.75M USD | Research and Development Expense |
| Selling, general and administration | 192.74M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-459.02M | $98.34M | $7.87M | $356.75M | $192.74M | -466.78% |
| 2026-03-31 | $-475.53M | $66.05M | $6.58M | $347.94M | $187.06M | -719.97% |
| 2025-12-31 | $-472.13M | $54.03M | $6.34M | $339.54M | $180.28M | -873.87% |
| 2025-09-30 | $-475.59M | $44.79M | $5.73M | $334.29M | $180.37M | -1061.80% |
| 2025-06-30 | $-461.53M | $40.88M | $4.83M | $319.95M | $177.63M | -1129.13% |
| 2025-03-31 | $-440.29M | $37.03M | $4.62M | $305.41M | $167.30M | -1188.86% |
| 2024-12-31 | $-425.74M | $36.50M | $4.17M | $301.29M | $156.78M | -1166.47% |
| 2024-09-30 | $-406.98M | $32.87M | $3.49M | $295.96M | $140.39M | -1238.10% |
| 2024-06-30 | $-405.06M | $31.31M | $3.34M | $305.35M | $127.68M | -1293.88% |
| 2024-03-31 | $-392.95M | $29.40M | $2.95M | $296.85M | $122.55M | -1336.41% |
| 2023-12-31 | $-391.49M | $26.82M | $2.88M | $295.53M | $119.90M | -1459.52% |
| 2023-09-30 | $-384.38M | $24.03M | $2.71M | $288.33M | $117.37M | -1599.59% |
| 2023-06-30 | $-374.57M | $20.15M | $2.59M | $271.46M | $120.67M | -1859.21% |
| 2023-03-31 | $-378.51M | $19.02M | $1.92M | $277.09M | $118.53M | -1990.40% |
| 2022-12-31 | $-389.05M | $14.24M | $1.70M | $279.91M | $121.67M | -2732.07% |
| 2022-09-30 | $-394.70M | (m) | (m) | $282.91M | (m) | (m) |
| 2022-06-30 | $-394.76M | (m) | (m) | $281.94M | (m) | (m) |
| 2022-03-31 | $-388.35M | (m) | (m) | $269.43M | (m) | (m) |
| 2021-12-31 | $-378.42M | (m) | (m) | $256.97M | $121.44M | (m) |
| 2021-09-30 | $-339.16M | (m) | (m) | $389.76M | (m) | (m) |
| 2021-06-30 | $-328.29M | (m) | (m) | $377.70M | (m) | (m) |
| 2021-03-31 | $-320.34M | (m) | (m) | $369.78M | (m) | (m) |
| 2020-12-31 | $-316.15M | $203.20M | $2.81M | $367.47M | $149.07M | -155.59% |
| 2020-09-30 | $-329.64M | $194.59M | $2.13M | $377.98M | (m) | -169.40% |
| 2020-06-30 | $-348.38M | $185.91M | $1.89M | $390.09M | (m) | -187.39% |
| 2020-03-31 | $-372.04M | $174.78M | $1.52M | $406.56M | (m) | -212.86% |
| 2019-12-31 | $-426.33M | $117.91M | $1.32M | $410.89M | $132.03M | -361.57% |
| 2019-09-30 | $-416.76M | $112.48M | $1.73M | $398.45M | (m) | -370.50% |
| 2019-06-30 | $-406.86M | $101.66M | $2.03M | $379.34M | (m) | -400.22% |
| 2019-03-31 | $-365.95M | $115.85M | $1.73M | $358.69M | (m) | -315.88% |
| 2018-12-31 | $-362.48M | $94.39M | $1.40M | $341.32M | $114.14M | -384.03% |
| 2018-09-30 | $-356.25M | $74.17M | (m) | $324.73M | (m) | -480.30% |
| 2018-06-30 | $-336.11M | $70.33M | (m) | $315.09M | (m) | -477.88% |
| 2018-03-31 | $-347.76M | $41.27M | (m) | $308.17M | (m) | -842.75% |
| 2017-12-31 | $-320.79M | $43.01M | (m) | $292.68M | (m) | -745.84% |
| 2017-09-30 | $-288.07M | (m) | (m) | $280.14M | (m) | (m) |
| 2017-06-30 | $-272.57M | (m) | (m) | $267.87M | (m) | (m) |
| 2017-03-31 | $-244.44M | (m) | (m) | $238.86M | (m) | (m) |
| 2016-12-31 | $-200.99M | $69.89M | (m) | $220.16M | (m) | -287.57% |
| 2016-09-30 | $-184.47M | (m) | (m) | $192.42M | (m) | (m) |
| 2016-06-30 | $-161.44M | (m) | (m) | $167.80M | (m) | (m) |
| 2016-03-31 | $-137.10M | (m) | (m) | $153.42M | (m) | (m) |
| 2015-12-31 | $-118.70M | $59.12M | (m) | $141.83M | (m) | -200.78% |
| 2015-09-30 | $-104.53M | (m) | (m) | $139.76M | (m) | (m) |
| 2015-06-30 | $-60.85M | (m) | (m) | $129.25M | (m) | (m) |
| 2015-03-31 | $-47.04M | (m) | (m) | $115.41M | (m) | (m) |
| 2014-12-31 | $-54.13M | $65.36M | (m) | $100.37M | (m) | -82.83% |
| 2014-09-30 | $-39.65M | (m) | (m) | $80.79M | (m) | (m) |
| 2014-06-30 | $-53.92M | $29.85M | (m) | $70.06M | (m) | -180.67% |
| 2014-03-31 | $-44.12M | $27.65M | (m) | $60.45M | (m) | -159.58% |
| 2013-12-31 | $-38.88M | $25.55M | (m) | $54.50M | (m) | -152.20% |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | $-24.78M | $25.11M | (m) | (m) | (m) | -98.69% |
| 2012-12-31 | $-23.00M | $25.11M | (m) | $41.04M | (m) | -91.59% |
| 2012-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $-16.63M | $21.84M | (m) | $31.25M | (m) | -76.16% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |